This is NOT the End for Immunotherapy in Parkinson's Disease - A Perspective from Early Drug Development Scientists

J Parkinsons Dis. 2022;12(8):2293-2296. doi: 10.3233/JPD-229008.
No abstract available

Publication types

  • Comment

MeSH terms

  • Drug Development
  • Humans
  • Immunotherapy
  • Parkinson Disease* / drug therapy
  • alpha-Synuclein

Substances

  • alpha-Synuclein